Could fluvoxamine keep COVID19 patients out of hospitals and intensive care units?

Since December 2019, when the first cases of coronavirus disease 2019 (COVID-19) were reported in Wuhan, China, SARS-CoV-2 has caused a global pandemic, with more than 75 million cases and over 1.6 million deaths worldwide (1). The international community has invested enormous resources in the devel...

Full description

Saved in:
Bibliographic Details
Published in:Croatian Medical Journal 2021, Vol.62 (1), p.95
Main Authors: Marčec, Robert, Likić, Robert
Format: Review
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since December 2019, when the first cases of coronavirus disease 2019 (COVID-19) were reported in Wuhan, China, SARS-CoV-2 has caused a global pandemic, with more than 75 million cases and over 1.6 million deaths worldwide (1). The international community has invested enormous resources in the development of safe and effective vaccines, which were registered and approved for widespread use in record time. Nevertheless, limited production capacities and vaccine hesitancy could impede a global post-COVID19 recovery, particularly in developing countries.
ISSN:0353-9504
1332-8166
DOI:10.3325/cmj.2021.62.95